Literature DB >> 31377762

High Thyroid Stimulating Receptor Antibody Titre and Large Goitre Size at First-Time Radioactive Iodine Treatment are Associated with Treatment Failure in Graves' Disease.

Wei Lin Tay1, Chiaw Ling Chng, Carolyn Sy Tien, Kelvin Sh Loke, Winnie Wc Lam, Stephanie Mc Fook-Chong, Aaron Kt Tong.   

Abstract

INTRODUCTION: Our study aimed to identify the factors associated with successful first-time radioactive iodine (RAI) treatment in patients with Graves' disease (GD).
MATERIALS AND METHODS: This is a restrospective study of patients with GD who were treated with RAI. Treatment success was defined as onset of permanent hypothyroidism or euthyroidism after 1 dose of RAI at 1-year follow-up.
RESULTS: There were 388 GD patients who underwent RAI treatment between January 2014 and December 2015. Of these, 74% achieved treatment success. Median time to achieve permanent hypothyroidism was 2 months. Male gender, smoking, higher antithyroid drug dosage, lower thyroid stimulating hormone (TSH) level, large goitre size and TSH receptor antibody (TRAb) titre at time of RAI were significantly associated with treatment failure. Multivariate analysis showed that larger goitre size and higher TRAb titre were associated with lower first-time RAI success.
CONCLUSION: Larger goitre size and higher TRAb titre predict lower success of RAI therapy in GD patients. Treatment decisions and strategies should be customised for patients who present with these characteristics.

Entities:  

Year:  2019        PMID: 31377762

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  2 in total

1.  Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.

Authors:  Rui-Ting Hu; De-Shan Liu; Bin Li
Journal:  BMC Endocr Disord       Date:  2020-05-29       Impact factor: 2.763

2.  Cross-sectional investigation of serum creatine kinase concentration in Graves disease patients treated with oral antithyroid drugs.

Authors:  Ying Cheng; Zhiyong Sun; Dapeng Zhong; Li Ren; Hang Yang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.